Pyxis Oncology Inc

+0.04 (+1.64%)

Biosion Licenses BSI-060T (Anti-Siglec-15) To Pyxis Oncology

Published: 03/29/2022 17:55 GMT
Pyxis Oncology Inc (PYXS) - Biosion Licenses Bsi-060t (anti-siglec-15) to Pyxis Oncology.
Biosion - Pyxis Oncology Will Be Responsible for Development and Commercialization of Bsi-060t (now Referred to As Pyx-106).
Biosion - Earns a $10 Million Upfront License Fee; Additional Milestone Payments & Royalties on Commercial Sales to Be Earned Upon Advancement of Pyx-106.
Biosion - Has Potential to Receive Milestone Payments for Pyx-106, Totaling Up to $222.5 Million & Single to Low Double-digit Royalties on Commercial Sales.
Biosion - Pyxis Oncology Plans on Submitting Ind for Pyx-106 to FDA by H2 of 2022 and Initiating a Phase 1 Trial Shortly Thereafter.
Biosion - Pyxis Oncology Has Opportunity to License Additional Preclinical Assets That Target Anti-siglec-15 Using Other Approaches to Treatment.